Table 5 LS-SBA - progression free survival by prognostic factors in only patients who received first-line chemotherapy

Gender

Male

20/24

20.2 (2.8 – 37.6)

1.69 (0.88 – 3.24)

0.115

Female

17/22

39.4 (17.3 – 61.5)

-

Primary tumour

Duodenum

28/34

23.8 (7.5 – 40.1)

-

(0.179)

Jejunum

5/7

28.6 (0 – 62.1)

0.50 (0.19 – 1.33)

0.164

Ileum

4/5

60.0 (17.1 – 100)

0.45 (0.15 – 1.32)

0.146

Disease status

Locally Advanced

2/2

50.0 (0 – 100)

-

Metastatic

35/44

28.4 (13.9 – 42.9)

1.35 (0.32 – 574)

0.683

Chemo 1^ST line

Doublet

15/18

25.0 (4.2 – 45.8)

-

Triplet

19/23

34.1 (12.5 – 55.7)

1.05 (0.53 – 2.09)

0.884

Chemo 2^nd line

No

18/17

27.9 (8.1 – 47.7)

-

Yes

19/19

31.6 (10.6 – 52.6)

1.17 (0.61 – 2.24)

0.633

Small Bowel Obstruction

None

22/28

19.8 (2.7 – 36.9)

-

Present

6/8

42.9 (6.2 – 79.6)

0.69 (0.27 – 1.75)

0.437

Weight loss

None

15/23

28.6 (6.1 – 51.1)

-

Present

13/13

23.1 (0 – 46.0)

1.29 (0.61 – 2.73)

0.499

CEA at baseline

Normal

6/9

66.7 (35.9 – 97.5)

-

Abnormal

25/27

12.8 (0 – 26.3)

3.18 (1.23 – 8.19)

0.017

Hemoglobin

Normal

8/10

48.0 (15.9 – 80.1)

-

Abnormal

25/29

20.5 (4.6 – 36.4)

1.88 (0.83 – 4.24)

0.130

Albumin

Normal

17/22

44.4 (22.1 – 66.7)

-

Abnormal

16/17

6.7 (0 – 19.4)

2.29 (1.12 – 4.66)

0.023

LDH

Normal

14/18

34.4 (10.9 – 57.9)

-

Abnormal

15/16

20.0 (0 – 40.2)

1.48 (0.70 – 3.15)

0.310

Alk.Ph

Normal

18/23

34.8 (13.0 – 56.6)

-

Abnormal

15/16

18.8 (0 – 38.0)

1.32 (0.66 – 2.62)

0.437

ALT

Normal

25/30

31.2 (13.6 – 48.8)

-

Abnormal

7/8

16.7 (0 – 45.7)

1.95 (0.82 – 4.61)

0.131

Platelets

Normal

17/24

43.6 (21.8 – 65.4)

-

Abnormal

17/17

11.8 (0 – 27.1)

2.32 (1.14 – 4.73)

0.020